The report is an essential source of information and analysis on the global Gallbladder Cancer Therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Gallbladder Cancer Therapeutics Market is Forecast to Decline Up to 2018:

GlobalData's analysis estimated the gallbladder cancer therapeutics market to be worth $156.0m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 2.0% for the next eight years to reach $148.68m by 2018. The decline in the gallbladder cancer therapeutics market is primarily due to the patent expiries of Gemzar and Xeloda, which are expected to leave the market vulnerable to generics.

The Gallbladder Cancer Therapeutics Market has Significant Unmet Need:

GlobalData has found that the gallbladder cancer therapeutics market has significant unmet needs. Due to the limited efficacy and safety profiles of the current market products there is considerable scope for new entrants to capture market value. There exists a huge potential for products using new technology with reduced side effects. New drugs entering the market with increased overall survival and safety could capture the market share.

Scope:

Companies Mentioned:

Reasons to Buy:

For more information visit http://www.researchandmarkets.com/research/5877f2/gallbladder_cancer